New study reveales 12 sequence variants that affect the risk of ET
Scientists at deCODE genetics and their collaborators have revealed 12 sequence variants that affect the risk of ET, (Essential tremor) providing important insights into its pathogenesis.
A sequence variant that increases risk of pregnancy loss
Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature Structural and Molecular Biology titled “Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination”.
GIPR Gene does not affect bone health
The results from a large collaborative effort show that variants in the GIPR gene are not associated with an increased risk of fracture or lowered BMD.
A study of the genetics of pericarditis increases understanding of newly approved drug treatment
Sequence variants that protect against pericarditis have been discovered at a genomic locus encoding interleukin-1 immune cytokines. A newly approved drug treatment for pericarditis inhibits these cytokines and new a study from deCODE genetics and collaborators can contribute to the further development of this treatment.
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.